Capivasertib API

Mechanism of action

Capivasertib inhibits all three AKT isoforms (AKT1, AKT2, AKT3).
AKT is a central signaling node in the PI3K/AKT/mTOR pathway, regulating cell proliferation, survival, and metabolism.
By blocking AKT kinase activity, capivasertib:

Inhibits phosphorylation of downstream AKT substrates
Suppresses tumor cell growth and survival
Overcomes resistance to endocrine therapy driven by PIK3CA mutations, AKT1 mutations, or PTEN loss


Demonstrates antitumor activity both as monotherapy and in combination with endocrine agents.

Indication

"Approved indication (FDA):

In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)‑positive, HER2‑negative, locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations, following disease progression on endocrine therapy."